825618-64-2Relevant academic research and scientific papers
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity
Howard, Steven,Berdini, Valerio,Boulstridge, John A.,Carr, Maria G.,Cross, David M.,Curry, Jayne,Devine, Lindsay A.,Early, Theresa R.,Fazal, Lynsey,Gill, Adrian L.,Heathcote, Michelle,Maman, Sarita,Matthews, Julia E.,McMenamin, Rachel L.,Navarro, Eva F.,O'Brien, Michael A.,O'Reilly, Marc,Rees, David C.,Reule, Matthias,Tisi, Dominic,Williams, Glyn,Vinkovi?, Mladen,Wyatt, Paul G.
, p. 379 - 388 (2009)
Here, we describe the identification of a clinical candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment. Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive tar
PHARMACEUTICAL COMPOUNDS
-
Page/Page column 228-229, (2010/11/28)
The use of a compound for the manufacture of a medicament for the prophylaxis or treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (e.g. JAK2 or JAK3), C-abl, PDKl , Chk (e.g. Cbkl or Chk2),
PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES
-
Page/Page column 172, (2008/06/13)
The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions con
